Breaking news on cystic fibrosis
NIH Awards $1.2 Million To Study Protein Misfolding Diseases published
Fri, 03 Sep 2010 04:00:00 PDT
Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell's protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis...
In Cystic Fibrosis Patients, Vitamin D May Treat And Prevent Allergic Reaction To Mold published
Sun, 29 Aug 2010 00:00:00 PDT
Vitamin D may be an effective therapy to treat and even prevent allergy to a common mold that can cause severe complications for patients with cystic fibrosis and asthma, according to researchers from Children's Hospital of Pittsburgh of UPMC, the University of Pittsburgh School of Medicine and Louisiana State University School of Medicine. Results of the study, led by Jay Kolls, M.D., Ph.D...
Luminex Announces Commercial Launch Of New Cystic Fibrosis Test published
Sat, 28 Aug 2010 01:00:00 PDT
Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, announced the full commercial launch of its xTAG® Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours...
News From The Journal Of Clinical Investigation: Aug. 25, 2010 published
Sat, 28 Aug 2010 00:00:00 PDT
BACTERIOLOGY: Antifreeze molecule enhances survival of bacteria-carrying ticks Ticks can carry and transmit to humans disease-causing bacteria...
News From The Journal Of Clinical Investigation: Aug. 16, 2010 published
Tue, 17 Aug 2010 05:00:00 PDT
PULMONARY: Can vitamin D reduce a complication of cystic fibrosis? The lungs of most individuals with cystic fibrosis are colonized by the mold Aspergillus fumigatus. In some this causes a condition known as allergic bronchopulmonary aspergillosis (ABPA), which is characterized by wheezing, lung infiltration by immune cells, and lung scarring, while others remain disease free...
"Improving Access To Clinical Trials Act" Passes U.S. Senate In Victory For CF Advocates published
Tue, 10 Aug 2010 00:00:00 PDT
The U.S. Senate has passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits...
Home Care Equivalent To Hospital Care For Some Patients With Cystic Fibrosis published
Thu, 08 Jul 2010 01:00:00 PDT
Patients with cystic fibrosis (CF) recover from exacerbations equally well if they are treated at home or in a hospital, according to researchers from Johns Hopkins University. Furthermore, longer treatment with antibiotics does not appear to offer any additional benefit over shorter courses...
Teens Urge Congress To Help Their Siblings With Cystic Fibrosis published
Wed, 23 Jun 2010 04:00:00 PDT
Teens from across the United States whose siblings have cystic fibrosis will press their elected officials in Washington, D.C., June 24, to fund drug research and increase access to clinical trials for those with rare diseases. Their goal is to speed the development of new drugs for people who need them most...
ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections published
Sat, 19 Jun 2010 01:00:00 PDT
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation)...
Detection Of MRSA In Cystic Fibrosis Patients Associated With Shorter Survival published
Fri, 18 Jun 2010 04:00:00 PDT
Patients with cystic fibrosis (CF) who have Methicillin-resistant Staphylococcus aureus (MRSA) detected in their respiratory tract have worse survival compared to CF patients without MRSA, according to a study in the June 16 issue of JAMA. The most common cause of death in CF is respiratory failure secondary to pulmonary infection...
Eurand Announces Data On Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs To FDA-Approved ZENPEP(R) published
Fri, 18 Jun 2010 00:00:00 PDT
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V...
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus published
Thu, 03 Jun 2010 14:00:00 PDT
Centocor Ortho Biotech Inc. announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases...
'Orphan Drug' Research Offers Hope published
Thu, 03 Jun 2010 00:00:00 PDT
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S...
Insight Into The Future Of Cystic Fibrosis Offered By Older Patients published
Sat, 22 May 2010 00:00:00 PDT
An emerging population of middle-aged cystic fibrosis patients contains significantly more females and includes a large proportion of patients who lived for decades without a diagnosis or specialized care, according to research published by researchers at National Jewish Health...
NIH Director Francis Collins And CF Foundation To Brief U.S. Senate On Advancing Disease Research published
Thu, 20 May 2010 02:00:00 PDT
National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., will lead a briefing on Capitol Hill Thursday, May 20, to discuss how funding for medical research at the NIH can be used more quickly to create new therapies for patients and save lives...
Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results Of Aeroquin(TM) (MP-376) Treatment In Cystic Fibrosis Patients published
Thu, 20 May 2010 01:00:00 PDT
Mpex Pharmaceuticals, Inc. announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans...
Gregory Downey, MD, Honored For Scientific Accomplishments published
Wed, 19 May 2010 05:00:00 PDT
Gregory Downey, MD, received the 2010 Recognition Award for Scientific Accomplishments at the American Thoracic Society's (ATS) International Conference on Monday, May 17. Dr. Downey, Executive Vice President of Academic Affairs and Professor of Medicine, Pediatrics and Immunology at National Jewish Health, has over 190 publications to his credit...
MP-376 Safe And Effective For Treatment Of P. Aeruginosa In CF Patients published
Mon, 17 May 2010 03:00:00 PDT
New possible treatment to treat P. aeruginosa in cystic fibrosis (CF) patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans. Approximately 80 percent of CF patients develop chronic P. aeruginosa lung infection, and antibiotic resistance is an increasing problem...
Aradigm Receives FDA Clearance For Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Pediatric Patients With Cystic Fibrosis published
Fri, 07 May 2010 00:00:00 PDT
Aradigm Corporation (OTCBB:ARDM) (the "Company") announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application...
Use Of Antibiotic By Children With Cystic Fibrosis Does Not Result In Improved Lung Function published
Wed, 05 May 2010 04:00:00 PDT
Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA. "A vicious cycle of infection and inflammation causes progressive lung destruction and premature death in patients with cystic fibrosis (CF)...
Cystic Fibrosis Foundation Launches National Cycling Series To Benefit Critical Research And Care published
Tue, 04 May 2010 19:00:00 PDT
Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP® CF Cycle for Life begins in San Francisco on June 26. The event's title sponsor is Eurand N.V...
Pigs Provide Clues On Cystic Fibrosis Lung Disease published
Thu, 29 Apr 2010 02:00:00 PDT
Aided by a new experimental model, scientists are a step closer to understanding how cystic fibrosis (CF) causes lung disease in people with the condition. The findings, published online April 28 in the journal Science Translational Medicine, could help improve treatments for lung disease, which causes most of the deaths and disability among people with CF...
Cystic Fibrosis: New Understanding Of Gating Mechanism Of CFTR Chloride Channel published
Tue, 27 Apr 2010 04:00:00 PDT
New research advances our understanding of the gating mechanism of the CFTR, the chloride channel mutated in cystic fibrosis patients. The study by Tzyh-Chang Hwang and colleagues (University of Missouri), and accompanying Commentary by Laszlo Csanady (Semmelweis University) appear in the May issue of the Journal of General Physiology...
New Drug May Treat Cystic Fibrosis, Other Diseases Caused By 'Nonsense Mutations' published
Tue, 27 Apr 2010 00:00:00 PDT
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease...
Infliximab Successfully Treats Cystic Fibrosis And Crohn's Disease published
Tue, 20 Apr 2010 05:00:00 PDT
Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive...
)
|
|
